Related Experiment Video
Updated: May 31, 2026
07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a)
Arif U Hasan1, Koji Ohmori, Takeshi Hashimoto
1Department of Cardiorenal Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Biochemical and Biophysical Research Communications
|July 12, 2011
Summary
Pioglitazone promotes preadipocyte proliferation by downregulating p16 expression via peroxisome proliferator-activated receptor gamma (PPARγ). This study elucidates the mechanism behind pioglitazone
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- Pioglitazone is a peroxisome proliferator-activated receptor (PPAR)γ ligand known to induce preadipocyte proliferation.
- The precise molecular mechanisms underlying pioglitazone-induced preadipocyte proliferation remain incompletely understood.
Purpose of the Study:
- To investigate the role of PPARγ and pioglitazone in regulating cell-cycle kinetics, focusing on cyclin-dependent kinase inhibitors.
- To elucidate the mechanism by which pioglitazone influences preadipocyte proliferation at the molecular level.
Main Methods:
- Utilized 3T3-L1 preadipocytes to study the effects of pioglitazone and PPARγ.
- Analyzed cell-cycle progression (S and G2/M phases) and p16 mRNA expression.
- Employed PPARγ overexpression and luciferase reporter assays to assess transcriptional regulation.
Main Results:
- Pioglitazone enhanced preadipocyte proliferation by promoting cell-cycle entry into S and G2/M phases.
- Pioglitazone treatment led to a significant decrease in p16 mRNA expression.
- PPARγ was confirmed as a key regulator of p16 mRNA transcription, with its downregulation effect augmented by pioglitazone.
Conclusions:
- Pioglitazone stimulates preadipocyte proliferation in a cell-cycle-dependent manner.
- The mechanism involves the downregulation of p16 (also known as p16Ink4a) expression mediated by PPARγ.
- This finding provides critical insights into the molecular pathways governing adipogenesis and the action of pioglitazone.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...